Ponesimod information

Ponesimod
Clinical data
Trade names	Ponvory
Other names	ACT-128800
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Ponesimod;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L04AE04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	2 main metabolites
Elimination half-life	31–34 hrs
Excretion	Feces (57–80%, 26% unchanged), urine (10–18%)
Identifiers
	IUPAC name (2Z,5Z)-5-{3-Chloro-4-[(2R)-2,3-dihydroxypropoxy]benzylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one;
CAS Number	854107-55-4;
PubChem CID	11363176;
DrugBank	DB12016;
ChemSpider	9538103;
UNII	5G7AKV2MKP;
KEGG	D11215;
ChEMBL	ChEMBL1096146;
CompTox Dashboard (EPA)	DTXSID50234631 ;
Chemical and physical data
Formula	C23H25ClN2O4S
Molar mass	460.97 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC/N=C\1/N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C;
	InChI InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1; Key:LPAUOXUZGSBGDU-STDDISTJSA-N;

Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis.^[4]^[9] It is a sphingosine-1-phosphate receptor modulator.^[4]

The most common side effects include upper respiratory tract infection, hepatic transaminase elevation, and hypertension.^[4]^[5]^[9]

Ponesimod was approved for medical use in the United States in March 2021,^[4]^[9] and in the European Union in June 2021.^[10]

^ ^a ^b "Ponvory APMDS". Therapeutic Goods Administration (TGA). 24 March 2022. Retrieved 4 April 2022.
^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Retrieved 2 January 2023.
^ "Summary Basis of Decision (SBD) for Ponvory". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
^ ^a ^b ^c ^d ^e "Ponvory- ponesimod tablet, film coated Ponvory- ponesimod kit". DailyMed. Archived from the original on 21 January 2022. Retrieved 31 March 2021.
^ ^a ^b Cite error: The named reference Ponvory EPAR was invoked but never defined (see the help page).
^ "Ponvory Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ Cite error: The named reference Brossard was invoked but never defined (see the help page).
^ Cite error: The named reference Reyes was invoked but never defined (see the help page).
^ ^a ^b ^c "Janssen Announces U.S. FDA Approval of Ponvory (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio (teriflunomide) in Reducing Annual Relapses and Brain Lesions" (Press release). Janssen. 19 March 2021. Archived from the original on 19 March 2021. Retrieved 19 March 2021 – via PR Newswire.
^ "European Medicines Agency Approval of Ponesimod". 24 March 2021. Archived from the original on 4 August 2021. Retrieved 4 August 2021.

[Ponvory_APMDS-1] "Ponvory APMDS". Therapeutic Goods Administration (TGA). 24 March 2022. Retrieved 4 April 2022.

[2] "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Retrieved 2 January 2023.

[3] "Summary Basis of Decision (SBD) for Ponvory". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

[Ponvory_FDA_label-4] "Ponvory- ponesimod tablet, film coated Ponvory- ponesimod kit". DailyMed. Archived from the original on 21 January 2022. Retrieved 31 March 2021.

[Ponvory_EPAR-5] Cite error: The named reference Ponvory EPAR was invoked but never defined (see the help page).

[6] "Ponvory Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[Brossard-7] Cite error: The named reference Brossard was invoked but never defined (see the help page).

[Reyes-8] Cite error: The named reference Reyes was invoked but never defined (see the help page).

[Janssen_PR-9] "Janssen Announces U.S. FDA Approval of Ponvory (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio (teriflunomide) in Reducing Annual Relapses and Brain Lesions" (Press release). Janssen. 19 March 2021. Archived from the original on 19 March 2021. Retrieved 19 March 2021 – via PR Newswire.

[10] "European Medicines Agency Approval of Ponesimod". 24 March 2021. Archived from the original on 4 August 2021. Retrieved 4 August 2021.

Ponesimod information

and 23 Related for: Ponesimod information

Ponesimod

Multiple sclerosis

Ceramide

Avacincaptad pegol

Etrasimod

ATC code L04

Fingolimod

Sphingosine

Serine

Siponimod

Ozanimod

Lysophosphatidylcholine

Myriocin

Oleoylethanolamide

Outline of immunology

Lysophosphatidic acid

Safingol

Lysophospholipid receptor

Ceramidase

Management of multiple sclerosis

Multiple sclerosis drug pipeline

Sphingosine kinase

Lysophosphatidic acid receptor